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ABSTRACT 
Objective: The present study was conducted to develop a simple and precise analytical method for the estimation of ticagrelor in tablet formulation. 
Methods: Reverse Phase HPLC was used for method development and validation studies of ticagrelor. The optimum chromatographic conditions 
comprised of C18 column (Kromasil, 250×4.6 mm, 5 µ) as the stationary phase and aqueous buffer (containing 0.5 ml formic acid and triethylamine 
each in water) and acetonitrile in the ratio of 50:50 v/v as the mobile phase. The flow rate was 1.3 ml/min with detection at 256 nm and a run time 
of 6 min. Forced degradation studies were conducted and the isocratic mode was modified to a gradient mode to make the method stability 
indicating in nature. 
Results: The retention time of ticagrelor was 3.372 min. The linearity studies indicated that the range of the developed method was 20-90 ppm 
with a correlation coefficient of 0.9956. The method was specific with a percent mean recovery was found to be 99.93%.. The % RSD in the 
precision studies was 0.069. The validated method was applied to conduct the assay of ticagrelor in tablets and the with a percent mean 
recovery of 99.82%. The modified method was capable of resolving 13 related substances from the ticagrelor peak in the forced degradation 
studies. 
Conclusion: The developed and validated RP-HPLC isocratic method was simple, accurate and precise as per the ICH guidelines. It was suitable for 
the analysis of ticagrelor in bulk and tablet formulation. The modified gradient method can be used to resolve the in-process impurities and related 
substances and can be directly applied to liquid chromatography hyphenated with mass spectroscopy (LC/MS) studies with minor modifications for 
identification of related substances. 
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Chromatography is a powerful separation method that finds 
application in all branches of science which is used for method 
development. High Performance Liquid Chromatography or High 
Pressure Liquid Chromatography (HPLC) is mainly a 
chromatography technique that can separate a mixture of 
compounds and is used in biochemistry and analytical chemistry to 
identify, quantify and purify the individual components of a mixture 
of analytes by distributing between the mobile phase (a flowing 
liquid) and a stationary phase (sorbents packed inside a column). 
Ticagrelor is newly introduced into the market, hence the data on 
the qualitative and quantitative estimation of this drug is limited. It 
is marketed as a tablet for the treatment of thrombosis. It reduces 
the rate of thrombotic cardiovascular events in patients with the 
acute coronary syndrome. It belongs to the class of triazolo 
pyrimidines which are polycyclic aromatic compounds containing 
triazole ring fused to a pyrimidine ring. Ticagrelor and its major 
metabolite reversibly interact with the platelet P2Y12 ADP-receptor 
to prevent signal transduction and platelet activation. It is a white 
crystalline powder with an aqueous solubility of approximately 
10µg/ml at room temperature. It has a log P of 2.30, pKa of strong 
acidic function 12.94 and strong basic function 2.90. It prevents 
platelet aggregation and thrombus formation in atherosclerotic 
disease which reduces chances of cardiac arrest due to blockage [1]. 
The marketed formulation of ticagrelor replaced clopidogrel-
containing formulations due to higher efficacy and lower side 
effects. It was approved for use in the European Union by the 
European Commission on December 3, 2010, by the US Food and 
Drug Administration on July 20, 2011. This antiplatelet drug 
formulation was developed and marketed by AstraZeneca, the 
patent was granted on 10th June 2008 and patent expire on 3rd 
December 2018. The clinical evidence for the effectiveness of 
ticagrelor was derived from Plato, a randomized double-blind study 
comparing ticagrelor with clopidogrel. This product is used to treat 
people who have had a recent heart attack or severe chest pain that 
happened because their heart was not getting enough oxygen or are 
treated with a procedure to open blocked arteries in the heart [2-4]. 
A literature search revealed very few papers on analytical methods 
of this drug. One research paper has reported a UV method of 
analysis and another one has reported a HPLC method of analysis for 
ticagrelor using UV detector [5-6]. Hence the aim of this study was to 
develop a simple, accurate and precise RP-HPLC analytical method 
for the estimation of ticagrelor in tablet formulation. 
 
 
Fig. 1: Chemical structure of ticagrelor 
 
MATERIALS AND METHODS [7-9] 
Chemicals and reagents 
Ticagrelor reference standard was obtained as a gift sample from 
Watson® Pharmaceuticals. Methanol and acetonitrile (HPLC grade), 
MilliQ water. hydrochloric acid (AR) 37%, sodium hydroxide (AR 
grade), orthophosphoric acid (HPLC grade) 85%, ammonium acetate 
(GR), potassium dihydrogen phosphate (AR), hydrogen peroxide 
(ACS) 50%, formic acid (AR), triethylamine (HPLC grade), sodium 
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lauryl sulphate, polysorbate 80 (GR) were procured from Merck® 
and Fischer Scientific®.  
Instruments used  
The HPLC system used was an Agilent 1260 infinity equipped with a 
quaternary solvent pump, a thermostated autosampler, degasser, 
UV/VWD detector and a column oven. A double beam UV-Visible 
spectrophotometer (Shimadzu 1800), USP Type II-Paddle apparatus 
(Labindia DS2000 with Ismatec high precision multichannel pump as 
autosampler), photo stability chamber (Atlas Suntest XLS+), HPLC water 
purifier (Millipore–Merck Millipore), orbital shaker (Thermo scientific) 
and a centrifuge (REMI research centrifuge) were used for this analysis. 
Preparation of solutions 
UV studies 
Preparation of standard stock solution (10 ppm) 
1 mg of ticagrelor reference standard was weighed accurately and 
transferred into a 100 ml volumetric flask. 30 ml diluent 
(acetonitrile: water 90:10 v/v) was added and the mixture was 
sonicated. The solution was diluted up to the mark with the diluent 
to give the standard stock solution. The λmax was determined using 
UV-VIS spectrophotometer. A working standard range from 2 to 7 
ppm was prepared from the stock solution of 10 ppm and used for 
linearity studies. 
Preparation of standard stock solution (90 ppm) 
25.0 mg of ticagrelor reference standard was weighed and 
transferred into a 25 ml volumetric flask to obtain a solution of 1000 
ppm in duplicate. 18 ml of methanol was added and sonicated. This 
solution was diluted to volume with methanol and mixed well. 9.0 
ml of standard stock solution was taken and diluted to 100 ml with 
diluent to give a standard stock solution of 90 ppm. 
Preparation of sample solution 
Five tablets of ticagrelor were weighed and transferred to 250 ml 
volumetric flask. 100 ml of water was added and sonicated for 1h to 
disperse the contents. Further 50 ml of water was added and the 
flask was kept in an orbital shaker at 50 rpm for 2h at room 
temperature (RT). The flasks were made up to the mark with water. 
The solution was then filtered using a 0.45µ Whatman Teflon filter. 
The filter was saturated by discarding the first 10 ml of filtrate. 5.0 
ml of the above filtrate was further diluted to 100 ml with diluent 
and mixed well to get the desired concentration. 
Preparation of buffers  
Preparation of buffered mobile phase  
0.5 ml and 0.5 ml of concentrated triethylamine solution were added 
using 1 ml pipette to 500 ml water, filtered through 0.45µ Nylon 6, 6 
membrane filter under suction and sonicated to degas. 
Preparation of other buffers  
6.8 g of potassium dihydrogen orthophosphate (KH2PO4) was added, 
filtered through 0.45µ Nylon 6, 6 membrane filter under suction and 
sonicated to degas. The pH was adjusted and maintained using 
concentrated orthophosphoric acid (OPA) to get pH 3.0, pH 4.5, pH 
6.8 and pH 7.5 respectively. 
0.1% and 0.2% of sodium lauryl sulphate (SLS) media: 10g and 20 g 
of SLS was dissolved in 10 L of water and sonicated. Similarly for 
preparing 0.1% and 0.2% of polysorbate (tween) media: 10 g and 20 
g of tween 80 were dissolved in 10 L of water and sonicated. 
Filter compatibility studies 
Filter compatibility tests were conducted to get a particle-free 
solution, which also should reproduce 100% response as per the 
respective content. The filtrate from each filter was compared with 
the centrifuged sample. The filter complying with all the parameters 
and showing same concentration as that of centrifuged sample was 
selected for further studies. 
Five intact tablets were weighed and transferred to 250 ml volumetric 
flask. 25 ml of miliQ water was added and sonicated for 10 min. 150 ml 
of acetonitrile was added and sonicated for 20 min with intermittent 
swirling. This was further diluted with acetonitrile mixed and filtered 
using 0.45µ Whatman Teflon filter. 10 ml of filtrate was discarded and 
further 5 ml was diluted to 100 ml with diluent. A 20 ml aliquot was 
subjected to centrifuge at 5000 rpm for 20 min and another 20 ml per 
filter was passed through the filters listed in fig. 2. 
 
 
Fig. 2: Filter study-Whatman 0.45 µm Nyl w/GMF, Whatman 0.7 
µm GF/F w/GMF, Millipore millex-HV Hydrophilic PVDF 0.45 
µm respectively 
 
The four solutions were chromatographed and were compared for 
peak shape and peak area. The filter that matched the centrifuged 
sample data was selected for further studies. 
Selection of diluent (HPLC compatible solvent) and solution 
stability studies 
The stability of the solution under study was established by keeping 
the solution at room temperature for 24 h. A standard solution was 
prepared using acetonitrile: water (90: 10 v/v, 50: 50 v/v, and 10: 
90 v/v), methanol: water (90: 10 v/v, 50: 50 v/v and 10: 90 v/v). 
The samples were injected at different time intervals of 5 min, 1 d 
and 1 w. 
Selection of flow rate and load volume 
Flow rates (0.8 ml/min. and 1.3 ml/min.) and loading volumes (1, 4, 
5, 6, 10, 20, 50 µl) were analyzed to get a precise and reproducible 
peak of ticagrelor with minimum tailing or fronting. 
Selection and optimization of mobile phase 
Various mobile phase compositions like acetonitrile: water (50: 50 
v/v, 90: 10 v/v, 60: 40 v/v, 40: 60 v/v and 10: 90 v/v), acetonitrile: 
methanol: water (80: 10: 10 v/v, 50: 25: 25 v/v, 30: 40: 30 v/v, 40: 
30: 30 v/v and 10: 45: 45 v/v), acetonitrile: TEA buffer in water (50: 
50 v/v ratio with 0.25 ml and 0.5 ml concentration of TEA per 500 
ml.), acetonitrile: TEA and FA buffer in water (50: 50 v/v ratio with 
0.25 ml: 0.25 ml and 0.5 ml: 0.5 ml concentration of TEA and FA per 
500 ml.), acetonitrile: buffer [pH range 3 to 7.5] (50: 50 v/v, 80: 20 
v/v and 20: 80 v/v) were evaluated in an effort to get symmetrical, 
sharp and reproducible peaks of ticagrelor. 
Selection and optimization of stationary phase 
Using the temporary developed chromatographic method a variety of 
columns with different attributes like polarity, particle size (3.5 µ and 
5 µ), carbon loading (C8 and C18) and dimensions were screened in an 
effort to arrive at the best column for the given analysis. Some of the 
columns studied were; Symmetry©C18 50 × 4.6 mm 3.5µ, Akzonobel 
Kromasil© C18 150 × 4.6 mm 5µ, Waters Xterra© C18 150 × 4.6 mm 
3.5µ, BDS Hypersil thermo© C8 50 × 4.6 mm 5µ, Fortis©C8 50 × 4.6 mm 
5µ and Agilent zorbax©RX C18 150 × 4.6 mm, etc. 
Selection of dissolution media by Biopharmaceutical 
Classification System (BCS) 
A ticagrelor standard solution was prepared and the final dilution 
was done using water, 0.1 N HCl, pH 4.5 buffer, pH 6.8 buffer, SLS 
media and tween media respectively. 
Five tablets were weighed and transferred to 250 ml volumetric 
flask.100 ml of water was added and sonicated for 1h to disperse the 
contents. Further 50 ml of water was added and the flask was kept 
in an orbital shaker at 50 rpm for 2h at RT. The solutions were made 
up to the mark with water. The solutions were mixed well and 
filtered using 0.45µ whatman teflon filter. The filter was saturated 
by discarding 10 ml of filtrate and 5.0 ml of above solution was 
diluted to 100 ml with diluent and mixed well. 
Tabassum et al. 
Int J App Pharm, Vol 9, Issue 4, 2017, 10-21 
12 
The % content of the ticagrelor into the respective media was 






















Where, AT = Peak area response of ticagrelor in the chromatogram 
obtained from the test solution. AS = Average peak area response of 
ticagrelor in the chromatograms obtained from replicate injections 
of standard solution. WS = Weight of ticagrelor standard taken in mg 
in standard stock solution. P = % Purity of ticagrelor standard. LC = 
Label claim of ticagrelor in mg per tablet. 
 
Dissolution studies of ticagrelor tablets 
 
Table 1: Dissolution testing conditions of ticagrelor tablets 
Apparatus USP type II (Paddle) 
Disso. volume 900 ml 
Speed 75 rpm 
Temperature 37 °C 
Time (min.) 5, 10, 20, 30, 45 and 60. 
 
Six tablets were weighed and transferred to 6 individual jars containing 
900 ml distilled water as dissolution media previously maintained at 37 
°C and the dissolution apparatus was set as per dissolution testing 
conditions. At specified intervals of time, 10 ml of sample aliquots were 
withdrawn and replenished with the same volume of fresh media. The 
samples were filtered with 0.45µ Whatman Teflon filter. Around 8 ml of 
the sample was discarded to saturate the filter. 
Similarly, the procedure was repeated using 0.1 N HCl, pH 4.5 buffer, 
pH 6.8 buffer, 0.1% SLS media, 0.2% SLS media and 0.1% Tween 80 
media, 0.2% Tween 80 media. 
The release of the ticagrelor into the respective media was 
calculated using formula;  
Where, AT = Peak area response of ticagrelor in the chromatogram 
obtained from test solution, AS = Average peak area response of 
ticagrelor in the chromatograms obtained from replicate injections 
of standard solution, WS = Weight of ticagrelor standard taken in mg 
in standard stock solution, P = % Purity of ticagrelor standard, LC = 
Label claim of ticagrelor in mg per tablet. 
Assay of ticagrelor tablets 
Ticagrelor standard solution and ticagrelor sample solution were 
prepared as discussed in 2.5.1 and 2.5.2. The samples were analysed 
using the developed chromatographic method and the % content of 
the drug in the tablets was determined. 
 
Table 2: Gradient sequence for related substances studies 
Time  (min) %  acetonitrile % FA: TEA 1:1 v/v in water 
0.00 45 55 
10.0 20 80 
20.0 50 50 
30.0 80 20 
40.0 45 55 
0.1 mg of known impurity (Acetal impurity, RS-13) was weighed accurately and transferred to 10 ml volumetric flask. 5 ml of diluent was added, 
sonicated and diluted to volume with diluent to get 10 ppm of impurity solution. The chromatograms of ticagrelor reference standard, drug sample 
and known impurity solutions were compared using the above-mentioned gradient run. 
 
Related substances studies 
The isocratic mode of the RP-HPLC method was modified to a 
gradient mode as given below with a run time of 40 min. 
Forced degradation studies 
With slight modifications, the developed chromatographic method 
was used to get accurate results. The optimized chromatographic 
method was kept same and run time was 12.0 min. Forced 
degradation studies of ticagrelor were conducted using solution 
stressors like distilled water, 0.1 N HCl, 0.1 N NaOH, hydrogen 
peroxide 50%. Photostability studies were conducted at a flux of 4.6 
× 1014 photons for 24 h and thermostability studies were conducted 
at a temperature of 80 °C for 24 h. The results were compared with 
the untreated standards. 
Five tablets were weighed accurately and transferred to 250 ml 
volumetric flask. 25 ml miliQ water was added and sonicated for 10 
min. 150 ml of acetonitrile was added and sonicated for 20 min. with 
intermittent swirling. 25 ml of respective stressor was added and 
heated at 80 °C for 24 h on a water bath previously maintained at 80 
°C. The sample was cooled to RT and neutralized. It was filtered 
using 0.45µ Whatman Teflon filter. 10 ml of filtrate was used for 
filter saturation and remaining 7 ml was used. 5 ml of filtrate was 
diluted to100 ml with diluent. The results were compared with the 
untreated sample. For the solid degradation analysis, the tablets 
were treated with the respective stressor and the results were 
compared with the untreated sample. 
Validation studies [10-15] 
Accuracy 
The accuracy of the method was determined by calculating % 
recovery. A known amount of ticagrelor was added to a placebo and 
the amounts were estimated by measuring the peak area. These 
studies were carried out in triplicate over the specified 
concentration range and the amount of ticagrelor was estimated by 
measuring the peak area ratios. The percentage recovery and 
standard deviation of percentage recovery were calculated. 
Precision 
The precision of the method was determined in terms of Intra-day 
and inter-day precision. For intra-day precision studies, a 
standard solution of 90 ppm was injected at various time intervals 
and percent related standard deviation (%RSD) was estimated.  
The inter-day precision was studied by injecting the same 
concentration of standard solution on consecutive days and the 
% RSD of the signal was calculated. The repeatability, 
intermediate precision and reproducibility of the developed 
method were determined. 
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Specificity 
Specificity is the ability to assess unequivocally the analyte in the 
presence of components etc. The blank (diluent), placebo, standard 
(90 ppm), sample (90 ppm) were prepared and injected to prove 
that the method developed was specific to ticagrelor. 
Linearity and range 
The linearity of the method was determined at six concentration 
levels ranging from 1-7 ppm of ticagrelor. A regression line was 
plotted of peak area v/s concentration. The correlation coefficient 
and equation of the regression line were calculated. The interval of 
lowest assessed concentration to the highest is the linearity range of 
the procedure. 
LOD and LOQ 
The detection limit of an individual analytical procedure is the 
lowest amount of analyte in a sample which can be detected but not 
necessarily quantitated as an exact value. The quantitation limit of 
an individual analytical procedure is the lowest amount of analyte in 
a sample which can be quantitatively determined with suitable 
precision and accuracy. 
Where, = the standard deviation of the response, Slope = slope of the 
calibration curve. 
Robustness  
Robustness of the developed method was studied by changing the 
flow rate and column temperature. The effect of flow rate was 
studied by keeping all chromatographic conditions same except the 
flow rate, i.e. 1.2 ml/min and in the next run 1.4 ml/min 
respectively. 
Similarly, the effect of temperature was studied by keeping all 
chromatographic conditions same except the temperature, i.e. 35 °C 
and in the next run with 25 °C respectively. 
System suitability 
The system suitability parameters like retention time, the number of USP 
theoretical plates, USP tailing, peak area and peak height were evaluated. 
RESULTS AND DISCUSSION 
UV studies 
The UV spectrum of ticagrelor in acetonitrile: water (90: 10 v/v) 
indicated the λmax to be 256 nm (fig. 3a). The response was linear 
and the regression equation was found to be y = 0.1331x+0.0858. 
The coefficient of correlation (R2) was found to be 0.9971(fig. 3b). 
Filter compatibility studies 
A temporary chromatographic method was used for selection of the 
best filter. Whatman Nylon w/GMF membrane filter pore size of 
0.45µ was selected after comparing the peak area and concentration 
(table 3) of centrifuged drug solution to other drug samples (fig. 4a 
and 4b). Based on these observations acetonitrile: water; 90: 10 v/v 
was selected as the diluent for further studies. The stability of drug 
sample was determined by keeping the sample in contact with the 
diluent for 5 min, 24 h and 1 w which indicated no change in the 
concentration (fig. 5a-5c and table 4). 
 
 
Fig. 3a: UV spectrum scan of ticagrelor in ACN: water (90: 10 v/v) 
 
 
Fig. 3b: Calibration curve and R2 of ticagrelor 
 
Table 3: Filter compatibility studies 
S. No. Sample analyzed from Observation 
Concentration (ppm) peak area 
1 Centrifuge 89.63 1134583 
2 0.45µ WhtNyl w/GMF 89.62 1134437 
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Fig. 4a: Chromatogram of the ticagrelor in the centrifuge solution 
 
Fig. 4b: Chromatogram of the ticagrelor filtered through 0.45µ Whatman Nylon w/GMF membrane filter 
 
Table 4: Effect of diluent on chromatogram after specified time intervals 
S. No. Analysis after Observation 
Retention time (min) peak area 
1 5 min 9.010 1134437 
2 24 h. 9.010 1134430 
3 1 w 9.010 1134432 
 
 
Fig. 5a: Chromatogram of ticagrelor standard solution after 5 min 
 
 
Fig. 5b: Chromatogram of ticagrelor standard solution after 24 h 
 
 
Fig. 5c: Chromatogram of ticagrelor standard solution after 1 w 
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Selection of mobile phase and stationary phase 
According to the observations of peak shape and retention time (fig. 
6), a flow rate of 1.3 ml and loading volume 10 µl was selected. 
Based on the data table 5, acetonitrile: formic acid: triethylamine in 
water 50: 50 v/v (0.5 ml: 0.5 ml) was selected as the mobile phase 
for the analysis (fig. 7). A variety of columns with different attributes 
like polarity, particle size, carbon loading and dimensions were 
screened in an effort to arrive at the best column for developing the 
analytical method of ticagrelor in API and tablet formulation (table 
6) Akzonobel Kromasil© C18 150 × 4.6 mm 5µ was selected as the 
column for the analysis of ticagrelor (fig. 8a-8b). 
 
 
Fig. 6: Effect of flow rate and loading volume on peak shape 
 
Table 5: Effect of mobile phase composition on chromatogram 
S. 
No 
Mobile phase composition Observation 
Retention time (min) peak shape 
1 Acetonitrile: water in 50: 50 v/v. 8.913 Tailing 
2 Acetonitrile: water 90: 10 v/v. 6.341 Sharp 
3 Acetonitrile: water in 60: 40 v/v. 9.009 Tailing 
4 Acetonitrile: water in 40: 60v/v 12.252 Sharp 
5 Acetonitrile: water 10: 90 v/v. 11.472 Shoulder 
6 Acetonitrile: methanol: water 80: 10: 10 v/v. 9.001 Sharp 
7 Acetonitrile: methanol: water 50: 25: 25 v/v. 7.882 Sharp 
8 Acetonitrile: methanol: water 30: 40: 30 v/v. 9.624 Sharp 
9 Acetonitrile: methanol: water 40: 30: 30 v/v. 12.113 Sharp 
10 Acetonitrile: methanol: water 10: 45: 45 v/v. 8.624 Sharp 
11 Acetonitrile: triethyl amine in water (TEA buffer) 50: 50 v/v 0.25 ml 9.991 Tailing 
12 Acetonitrile: triethyl amine in water (TEA buffer) 50: 50 v/v 0.5 ml. 9.100 Tailing 
13 Acetonitrile: formic acid: triethyl amine in water 50: 50 v/v 0.25 ml: 0.25 ml. 9.931 Sharp 
14 Acetonitrile: formic acid: triethyl amine in water 50: 50 v/v 0.5 ml: 0.5 ml 9.434 sharp 
15 Acetonitrile: buffer pH 3.0 in 50: 50 v/v 7.021 Merged 
16 Acetonitrile: buffer pH 4.5 in 50: 50 v/v 9.982 Merged 
17 Acetonitrile: buffer pH 6.8 in 50: 50 v/v. 3.718 Tailing 
18 Acetonitrile: buffer pH 7.5 in 50: 50 v/v. - - 
 
 
Fig. 7: Chromatogram of ticagrelor with acetonitrile: formic acid: triethylamine in water 50: 50 v/v (0.5 ml: 0.5 ml) as mobile phase 
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Table 6: Effect of stationary phase on chromatogram 
S. No. Stationary phase Observation 
Retention time (min) peak shape 
1 Symmetry©C18 50 × 4.6 mm 3.5µ 9.850 Sharp 
2 Waters Xterra© C18 150 × 4.6 mm 3.5µ 8.989 Broad peak 
3 Fortis©C8 50 × 4.6 mm 5µ 8.989 Symmetric 
4 Inertsil ODS© C18 250 × 4.6 mm 5µ 9.434 Sharp 
5 AkzonobelKromasil© C18 150 × 4.6 mm 5µ 9.001 Sharp 
6 BDS Hypersil thermo© C8 50 × 4.6 mm 5µ 13.001 Fronting 
7 YMC© C18 150 × 4.6 mm 5µ 14.101 Broad peak 
8 SupelcosilSupelco©C18 300 × 3 mm 3µ 9.130 Sharp peak 
9 Hypersil Thermo© C18 300 × 3 mm 5µ 8.022 Sharp peak 
10 Agilent ZORBAX©SB C18 150 × 4.6 mm 5µ 9.031 Sharp 
11 Agilent zorbax©RX C18 150 × 4.6 mm 5µ 7.812 Sharp 
12 Synergy Hydro Phenomenex© C18 50 × mm 5µ 7.992 Broad peak 
 
 
Fig. 8a: Chromatogram of ticagrelor using Inertsil ODS© C18 250 × 4.6 mm, 5µ 
 
 
Fig. 8b: Chromatogram of ticagrelor using akzonobel Kromasil© C18 150 × 4.6 mm, 5µ 
 
Selection of dissolution media by biopharmaceutical 
classification system (BCS) 
Ticagrelor is a class BCS IV drug hence the selection of the solvent 
for dissolution studies of ticagrelor tablets was crucial. After a series 
of trials using different solvents (table 7) 0.2% tween 80 was 
selected as the solvent (fig. 9). 
Dissolution studies and assay of ticagrelor tablets 
The results of dissolution studies indicated that the developed RP-
HPLC method was suitable for this purpose (table 8). The 
dissolution results indicated a release of 99.4% in 60 min. at 75 rpm 
(fig. 10a). The assay of ticagrelor tablets was conducted using the 
developed and validated RP-HPLC method and the drug content was 
found to be 99.9% (fig. 10b). 
 
Table 7: Effect of various media on the stability of ticagrelor 
S. No. Solvent Peak area % content 
Standard Sample 
1 Distilled water - - No peak 
2 0.1 N HCl 1921 1850 101.23 
3 pH 4.5 buffer 10421 10393 99.73 
4 pH 6.8 buffer 120105 121021 100.283 
5 pH 7.5 buffer - - No peak 
6 0.1 % SLS 1042301 1042498 99.63 
7 0.2% SLS 1042598 1042502 10.00 
8 0.1 % Tween 80 1075400 1075412 99.61 
9 0.2 % Tween 80 1134682 1132817 99.48 
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Fig. 9: Chromatogram of ticagrelor in 0.2% tween 80 in water as solvent 
 
Table 8: Release studies of ticagrelor in 0.2% tween 80 
S. No. Time (min) Peak area % release 
Standard Sample 
1 5 1134680 481342 42.26 
2 10 1134680 501212 44.02 
3 15 1134680 541822 47.58 
4 30 1134680 755817 66.38 
5 45 1134680 1084912 95.27 
6 60 1134680 1132817 99.48 
 
 
Fig. 10a: Chromatogram of ticagrelor showing release in 60 min. (Dissolution test) 
 
 
Fig. 10b: Chromatogram of ticagrelor sample (assay) 
 
Related substances (RS) and forced degradation studies (FD) 
The modified gradient RP-HPLC method with a run time of 40 min 
run was used for the determination of related substances in 
ticagrelor tablets after conducting the forced degradation studies. 
This method was found to be capable of resolving ticagrelor from 
thirteen related substances (fig. 11). 
The modified analytical method with a run time of 12.0 min was 
used for the determination of impurities generated in the 
ticagrelor API sample after conducting forced degradation using 
various stressors. The results obtained (table 9) indicated that 
the developed method was able to resolve all the degradation 
peaks from the ticagrelor (fig 12a-12f). 
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Fig. 11: Chromatogram of ticagrelorat 14.515 min with 13 related substances (RS) 
 
Table 9: Forced degradation studies of ticagrelor 
S. No. Stressor condition Retention time of API (min) Impurities generated 
1. Thermostability 6.071 3 
2 Photostability 6.076 3 
3 Hydrolytic degradation 6.102 10 
4 Oxidative degradation 6.100 11 
5 Acid hydrolysis 6.089 13  
   and 1 Major impurity at 6.730 min 
6 Alkaline hydrolysis 6.085 19 
 
 
Fig. 12a: Chromatogram of ticagrelor (thermal stability) 
 
 
Fig. 12b: Chromatogram of ticagrelor (photostability) 
 
 
Fig. 12c: Chromatogram of ticagrelor (hydrolytic degradation) 
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Fig. 12d: Chromatogram of ticagrelor (oxidative degradation) 
 
 
Fig. 12e: Chromatogram of ticagrelor (acid hydrolysis) 
 
 
Fig. 12f: Chromatogram of ticagrelor (alkaline hydrolysis) 
 
Validation studies 
The developed RP-HPLC method was validated according to the 
International Conference on Harmonization (ICH) Q2 guidelines for 
various parameters like accuracy, precision, specificity, linearity and 
range, LOD and LOQ, robustness and system suitability. 
Accuracy 
The accuracy of the developed method was evaluated by conducting 
recovery studies. The accuracy was calculated by assay method at 
concentrations of 50%, 100% and 150%. The calculated amount of 
ticagrelor stock solutions were spiked to get the concentrations. The % 
mean recovery of spiked samples was found to be 99.82% (table 10). 
Precision 
The intra-day precision studies were performed using ticagrelor 
reference standard solution of 90 ppm. The solution was injected at 
various time intervals and percent related standard deviation (% 
RSD) was determined. The inter-day precision was studied by 
injecting the same concentration of standard solution on consecutive 
days and the % RSD was calculated. The relative standard deviation 
obtained from 12 assay results was found to be 0.069% (table 11). 
 
Table 10: Accuracy studies of ticagrelor 
Level  Conc. added (µg/ml)  Conc. found  (µg/ml)  % recovery  % mean recovery  
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Table 11: Precision studies of ticagrelor 
Precision parameter Peak area SD % RSD 
Run 1 Run 2 Run 3 Mean 
Reproducibility 1389984 1389953 1388300 1389412 963.433 0.069 
Intermediate precision 1389986 1389958 1388303 1389416 963.699 0.069 
repeatability 1389983 1389956 1388309 1389416 958.785 0.069 
 
Table 12: Specificity studies of ticagrelor 
S. No. Standard (Area AU) Sample (Area AU) 
1 138668 138650 
2 138764 138758 
3 138599 138596 
Mean 138677 138668 
SD 82.86736 82.48636 
%RSD 0.059756 0.059485 
 
 
Fig. 13: Linearity and range studies of ticagrelor 
 
Specificity 
No interferences were observed in the chromatogram of ticagrelor 
standard due to the presence of excipients and blank (table 12). 
Linearity and range 
A graph of peak area versus concentration (ppm) were plotted for 
ticagrelor at concentration range between 20-90 ppm. The linear 
regression equation and correlation coefficient (r2) were y= 
8268.2x+41452 and 0.995 respectively (fig. 13). 
LOD and LOQ 
The results of signal to noise ratio was compared with the response 
of ticagrelor standard. The LOD and LOQ were found to be 0.2887 
ppm and 0.8749 ppm respectively. 
System suitability 
System suitability tests were performed using ticagrelor standard 
and test solutions to check for compliance with specified parameters 
(table 13). 
 
Table 13: System suitability studies of ticagrelor 
S. No. Parameter Ticagrelor 
1 Retention time 3.305 
2 Number of theoretical plates 5538 
3 Tailing factor 0.85 
4 Peak area 1134680 
5 Peak height 190457 
 
Table 14: Robustness studies of ticagrelor 
Factor Level TR  Tailing factor 
Parameter: Flow rate   
1.2 ml/min -1 3.53 0.86 
1.3 ml/min 0 3.31 0.92 
1.4 ml/min +1 3.20 0.74 
Mean 3.34 0.84 
Parameter: Column temperature 
25 °C -5 3.48 0.75 
30 °C 0 3.32 0.88 
35 °C +5 3.14 0.81 
Mean 3.31 0.79 
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Robustness studies 
The changes were applied and system suitability parameters were 
checked, found to be within the acceptable limits. It was noted that 
trivial changes in temperature and flow rate does not affect the 
method and produces results which passes system suitability. Hence 
the method was robust (table 14). 
CONCLUSION 
A new RP-HPLC method for the determination of ticagrelor was 
developed and validated. The developed method was accurate, 
precise, specific and sensitive for the quantitative analysis of 
ticagrelor both in bulk drug and tablets. Validation studies 
indicated the method to be robust on minor variations in the 
chromatographic parameters. No attempt was made to quantify 
the degradation products in this research project. This method can 
be used for routine quality monitoring of ticagrelor and its tablets. 
This method can be extended for application in LC-MS for 
quantitative estimation of known and unknown impurities 
generated during forced degradation and related substance 
studies both for API and finished products of ticagrelor. 
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